A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Yi Li, Ji Wang, Xiaowei Ma, Li Tan, Yanli Yan, Chaofan Xue, Beina Hui, Rui Liu, Hailin Ma, Juan Ren, Yi Li, Ji Wang, Xiaowei Ma, Li Tan, Yanli Yan, Chaofan Xue, Beina Hui, Rui Liu, Hailin Ma, Juan Ren

Abstract

Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemradiotherapy than high rectal cancer. It needs to refine the selection of appropriate patients and irradiation modes for neoadjuvant chemoradiotherapy. Different therapeutic reactions to neoadjuvant chemoradiotherapy affect the type of surgical techniques, hence calling for the need of much attention. Furthermore, many problems such as accurate staging before surgery, selection of suitable neoadjuvant chemoradiotherapy method, and sensitivity prediction to preoperative radiotherapy need to be well settled.

Keywords: Rectal cancer; preoperative concurrent chemoradiotherapy.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

    1. Lemmens V, Steenbergen LV, Janssenheijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975-2007: Rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49:784–96.
    1. Glimelius B, editor Multidisciplinary treatment of patients with rectal cancer. Development during the past decades and plans for the future. Mechatronics and Automation (ICMA), 2012 International Conference on; 2012.
    1. Hwang K, Park IJ, Chang SY, Lim SB, Lee JL, Yong SY, Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. World J Gastroenterology; 2015. pp. 555–62.
    1. Brændengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L. et al. Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer. J Clinical Oncology. 2008;26:3687–94.
    1. R S, H B, W H, C R, C W, R F. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731–40.
    1. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124–30.
    1. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, benek MBjm, Pudełko M. et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiotherapy & Oncology Journal of the European Society for Therapeutic Radiology & Oncology. 2004;72:15–24.
    1. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–25.
    1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevicjelic L. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med. 2006;355:1114–23.
    1. Serra-Aracil X, Mora-Lopez L, Alcantara-Moral M, Caro-Tarrago A, Gomez-Diaz CJ, Navarro-Soto S. Transanal endoscopic surgery in rectal cancer. World J Gastroenterol. 2014;20:11538–45.
    1. Wang ZZ, Zhou ZX. Radiotherapy In Comprehensive Treatment Of Low Rectal Cancer Multidisciplinary Significance. Practical Oncology. 2011;26:13–16.
    1. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2012;30:3827–33.
    1. Nilsson PJ, Etten BV, Hospers GA, Påhlman L, Velde CJVD, Beets-Tan RG. et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer - the RAPIDO trial. Bmc Cancer. 2013;13:1–9.
    1. Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, Malinowska M, Krynski J, Kosakowska E. et al. Neoadjuvant treatment for unresectable rectal cancer: An interim analysis of a multicentre randomized study. Radiotherapy & Oncology. 2013;107:171–77.
    1. Pettersson D, Cedermark B, Holm T, Radu C, Påhlman L, Glimelius B. et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer †. Bri J Surgery. 2010;97:580–87.
    1. Park Chang, Seok-Byung Yong, Yoon Chan. et al. Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy. World J Gastroenterol. 2015;21:3274–81.
    1. Aoife Maguire, Kieran Sheahan. Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol. 2014;20:9850–61.
    1. Daniel Damin, Anderson Lazzaron. Evolving treatment strategies for colorectal cancer: A critical review of current therapeutic options. World J Gastroenterol. 2014;20:877–87.
    1. Park Chang. Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy. World J Gastroenterol. 2014;20:2023–29.
    1. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP. et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235:449–57.
    1. Rödel C, Grabenbauer GG, Papadopoulos T, Bigalke M, Günther K, Schick C. et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. International Journal of Radiation Oncologybiologyphysics. 2002;52:294–303.
    1. Wang FW, Wang HT, Yin XD, Zhang L, Zhang T, Zhang MZ. The value of neoadjuvantchemotherapy in rectal cancer in the Chinese. J Integr Med. 2011;17:22–24.
    1. Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. palliative care and end-stage colorectal cancer management:The surgeon meets the oncologist. World J of Gastroenterol. 2014;20:7602–21.
    1. Zhang Z. Radiation therapy for middle and low rectum cancer. Chinese Jounal of Surgery. 2014;34:854–856.
    1. Yeoh EK, Russo A, Botten R, Fraser R, Roos D, Penniment M. et al. Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function. Gut. 1998;43:123–7.
    1. Jin YN. A Hot Issue Of Low Rectal Cancer Radiotherapy. Surgical Theory And Practice. 2010;15:111–114.
    1. Gervaz PA, Wexner SD, Pemberton JH. Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy 1. J Am Coll Surgeons. 2002;195:387–94.
    1. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL. Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis. 2006;8:570–4.
    1. Urbano MTG, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ. et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65:907–16.
    1. Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:1–9.
    1. Caravatta L, Padula GDA, Picardi V, Macchia G, Deodato F, Massaccesi M. et al. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study. Acta Oncologica. 2011;50:1151–57.
    1. Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME. et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol. 2011;6:1–9.
    1. Wolff HA, Wagner DM, Conradi LC. Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: a planning study with clinical implications. Indengchemfundamen. 2012;102:30–7.
    1. Hartley A, Ho KF, Mcconkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol. 2005;78:934–8.
    1. Kocakova I, Svoboda M, Kubosova K, Chrenko V, Roubalova E, Krejci E. et al. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. Neoplasma. 2007;54:447–53.
    1. Xiao Q, Jin J. The principle of neoadjuvant and adjuvant radiotherapy for lower rectal carcinoma:discussion with surgeons. Chinese Journal of Practical Surgery. 2012;32:724–727.
    1. Veerasarn V, Phromratanapongse P, Lorvidhaya V, Lertsanguansinchai P, Lertbutsayanukul C, Panichevaluk A. et al. Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2006;89:1874–84.
    1. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT. et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology. 2012;13:579–88.
    1. De PA, Chiara SG, Friso ML, Beretta GD, Del PS, Pasetto L. et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006;17:246–51.
    1. Wen G, Zhang J, Chi F, Chen L, Huang S, Niu S. et al. Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy. International Journal of Medical Physics Clinical Engineering & Radiation Oncology. 2015;04:54–63.
    1. Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Köllingschlebusch K. et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2002;20:3983–91.
    1. Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N. et al. Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2003;56:1284–7.
    1. Jin J, Li YX, Liu YP, Wang WH, Song YW, Li T. et al. A Phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2006;64:725–9.
    1. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol. 2002;54:403–8.
    1. JC K, TW K, JH K, CS Y, HC K, HM C. et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol. 2005;63:346–53.
    1. Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M. et al. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. Oncology. 2007;73:169–76.
    1. Martin M, Cerezo L, Couñago F, Martin-Angulo M, Lopez M, Marin A. et al. A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol. 2007;30:340–5.
    1. Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer. 2007;97:1333–7.
    1. CS Y, TW K, JH K, WS C, HC K, HM C. et al. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Bio Phys. 2007;67:1020–6.
    1. Roh MS, Yothers GA, O'Connell MJ. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proceedings of the ASCO Annual Meeting Proceedings; 2011. p. 3503.
    1. Eagleton N. Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin. World J Gastroenterol. 2010;16:112–8.
    1. Carrato A. Adjuvant treatment of colorectal cancer. Zeitschrift Für Gastroenterologie Verhandlungsband. 1988;23:168–85.
    1. C A, L C, Lonardi S, Pinto C, Cordio S, Rosati G. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.
    1. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL. et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.
    1. Roedel C, Grabenbauer GG, Hohenberger W, Papadopoulos T, Sauer R, Roedel C. et al. O-0028 * PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH 5-FLUOROURACIL AND OXALIPLATIN VERSUS 5-FLUOROURACIL ALONE IN LOCALLY ADVANCED RECTAL CANCER: RESULTS OF THE GERMAN CAO/ARO/AIO-04 RANDOMIZED PHASE III TRIAL. Ann Oncol. 2012;13:679–87.
    1. Zhao HC, Gao C. Evaluation criteria of the efficacy of neoadjuvant therapy for colorectal cancer. J Digest Dis. 2011;31:253–255.
    1. Boxberger F, Albrecht H, Konturek PC, Reulbach U, Maennlein G, Meyer T. et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Medical Science Monitor International Medical Journal of Experimental & Clinical Research. 2010;16:19–30.
    1. Kekelidze M, D'Errico L, Pansini M, Tyndall A, Hohmann J. Colorectal cancer:Current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol. 2013;19:8502–14.
    1. Hospers GA, Punt CJA, Tesselaar ME, Cats A, Havenga K, Leer JWH. et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol. 2007;14:455–61.
    1. Des GG, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res. 2009;29:1615–20.
    1. Guetz GD, Schischmanoff O, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45:1890–6.
    1. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Eng J Med. 2003;349:247–57.
    1. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2010;28:3219–26.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–47.
    1. Yoshiaki Tsuchida MD, Patrick Therasse MD. Response evaluation criteria in solid tumors (RECIST): New guidelines. Medical & Pediatric Oncology. 2001;37:1–3.
    1. Habr-Gama A, Gama-Rodrigues J, Julião GPS, Proscurshim I, Sabbagh C, Lynn PB. et al. Local Recurrence After Complete Clinical Response and Watch and Wait in Rectal Cancer After Neoadjuvant Chemoradiation: Impact of Salvage Therapy on Local Disease Control. Int J Radiat Oncol Bio Phys. 2014;88:822–8.
    1. Belluco C, Paoli AD, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A. et al. Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies. Ann Surg Oncol. 2011;18:3686–93.
    1. Gerard JP, Francois Y, Nemoz C, Adeleine P. 55 Influence of the interval between pre-operative radiotherapy (preop-XRT) and surgery on the downstaging and sphincter preservation for the rectal cancer, the lyon R90 01 randomized trial. Journal of Thoracic & Cardiovascular Surgery. 1999;45:2396–2396.
    1. Lim S, Choi H, Sy, Kim D, Jung K, Hong Y, Chang H. et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008;248:243–51.
    1. Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM. et al. Metformin use and improved response to therapy in rectal cancer. Cancer Medicine. 2013;2:99–107.
    1. Trakarnsanga A, Ithimakin S, Weiser MR. Treatment of locally advanced rectal cancer: Controversies and questions. World J Gastroenterol. 2012;18:5521–32.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe